Sanzyme Biologics5642Sanzyme Biologics®, originally founded as Uni-Sankyo in 1969, is a pioneer in the field of probiotics. Presently, the company has established its market presence in over 40 countries worldwide, including the United States, Canada, Europe, Japan, South Korea, Australia, New Zealand, India, China, and Taiwan. Sanzyme Biologics operates state-of-the-art NSF certified facilities in Hyderabad, India, where it manufactures spore-forming probiotic strains such as Bacillus coagulans SNZ 1969®, Bacillus clausii SNZ 1971™, Bacillus subtilis SNZ 1972, and Saccharomyces boulardii SNZ 1986™. In the same facility, it also manufactures patented and clinically studied probiotic blend TriBac™.
Sanzyme Biologics' flagship strain, Bacillus coagulans SNZ 1969®, stands out for its resilient spore form, making it an excellent choice for food, supplement, and pharmaceutical product developers. It can withstand various processing conditions, gut pH levels, and bile salts, eliminating the need for a cold chain, unlike vegetative probiotic strains. Moreover, SNZ 1969® has US FDA GRAS status (for adults and infants), Health Canada approval, non-GMO project verification, and support from over 30 scientific publications highlighting its contributions to gut health, oral health, and women's health.
Bacillus coagulans SNZ 1969® could be incorporated into a wide range of food and beverage formats, including cereal bars, protein bars, meal replacements, breakfast cereals, tea, coffee, kombucha, cookies, seasonings, nuts, chocolates, lozenges, mint tablets, gummies, hard-boiled candies, health food drinks, and fat spreads. Additionally, this remarkable probiotic strain has undergone clinical studies, even extending to pets, specifically dogs, where it has demonstrated its positive impact on digestive health.
